跳至主要内容
临床试验/NCT01601938
NCT01601938撤回2 期

Effects of Selenium Replacement on Prognosis of Severe Sepsis and Septic Shock Patients and Their Initial Serum Selenium Level: a Randomized, Double-blind Placebo Controlled Phase 2 Study

Gil Joon Suh1 个研究点 分布在 1 个国家开始时间: 2012年9月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
撤回
发起方
试验地点
1
主要终点
28-day mortality

研究概览

简要总结

This study will be performed to determine whether selenium replacement reduces 28-day mortality of severe sepsis and septic shock patients, and to investigate whether selenium replacement contributes differently to the mortality reduction of the patients according to their initial serum selenium level.

详细描述

This study is a single center, randomized, double-blind, placebo controlled trial.

After the diagnosis of severe sepsis and septic shock, enrolled patients will be randomized. Then, selenium or placebo will be intravenously administered to them for 7 days. Hemodynamic and laboratory data will be recorded for 7 days and additional serum samples will be obtained at 0, 24, 72, and 168 hours post-treatment and stored. Mortality will be observed for 28 days.

An interim analysis will be conducted by the independent data safety monitoring board.

Serum selenium levels will be measured from the stored serum samples after the study completion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •age 18 or older
  • •clinical diagnosis of severe sepsis or septic shock

排除标准

  • •pregnancy or breast feeding
  • •age younger than 18
  • •advanced directive state to withhold treatment
  • •known allergy to selenium
  • •CPR or death within 24 hours after the diagnosis of severe sepsis or septic shock
  • •advanced malignancy without further treatment plan

研究组 & 干预措施

Selenium

Experimental

500 mcg of selenium (10mL) daily for 7 days

干预措施: selenium replacement (Dietary Supplement)

Placebo

Placebo Comparator

Placebo 10 mL (delivered from biosyn) for 7 days

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

28-day mortality

时间窗: 28 days

All cause mortality occurs within 28 days.

次要结局

  • Ventilator days(3 months)
  • Renal replacement therapy days(3 months)
  • Serum selenium level(At 0, 24, 72, 168 hours post-enrollment)
  • Oxidative stress marker(At 0, 24, 72, 168 hours post-enrollment)
  • Inflammatory markers(At 0, 24, 72, 268 hours post-enrollment)
  • Changes in severity scores(7 days)
  • Development of the new infection(3 months)
  • Vasopressor days(3 months)
  • ICU length of stay(3 months)
  • Mortality at hospital discharge(3 months)
  • 3-month mortality(3 months post-enrollment)

研究者

发起方
Gil Joon Suh
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Gil Joon Suh

Professor

Seoul National University Hospital

研究点 (1)

Loading locations...

相似试验